The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Late-Stage Oncology Drug Market Research Report 2025

Global Late-Stage Oncology Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1971211

No of Pages : 96

Ask Your Query
Synopsis
A late-stage oncology drug refers to a medication or treatment that has advanced through the initial phases of clinical trials (phases I and II) and is now being tested in phase III clinical trials or is awaiting regulatory approval for marketing. These drugs are typically intended for the treatment of cancer in patients who have advanced disease or have not responded well to standard treatments. Late-stage oncology drugs undergo rigorous testing to assess their safety, efficacy, and potential side effects in larger groups of patients before they can be approved for use in clinical practice.
The global Late-Stage Oncology Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Late-Stage Oncology Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Late-Stage Oncology Drug is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Late-Stage Oncology Drug include Roche, Merck & Co, Bristol Myers, Pfizer, Novartis, AstraZeneca, Johnson & Johnson, Eli Lilly and Company, Sanofi, AbbVie, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Late-Stage Oncology Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Late-Stage Oncology Drug.
The Late-Stage Oncology Drug market size, estimations, and forecasts are provided in terms of sales volume (kg) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Late-Stage Oncology Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Late-Stage Oncology Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Roche
Merck & Co
Bristol Myers
Pfizer
Novartis
AstraZeneca
Johnson & Johnson
Eli Lilly and Company
Sanofi
AbbVie
GSK
Amgen
Genentech
Daiichi Sankyo Group
Aveo Oncology
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory or Lung Cancer
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Late-Stage Oncology Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Late-Stage Oncology Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report. 
Index
1 Late-Stage Oncology Drug Market Overview
1.1 Product Definition
1.2 Late-Stage Oncology Drug by Type
1.2.1 Global Late-Stage Oncology Drug Market Value Comparison by Type (2024-2030)
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Late-Stage Oncology Drug by Application
1.3.1 Global Late-Stage Oncology Drug Market Value by Application (2024-2030)
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory or Lung Cancer
1.3.7 Other
1.4 Global Late-Stage Oncology Drug Market Size Estimates and Forecasts
1.4.1 Global Late-Stage Oncology Drug Revenue 2019-2030
1.4.2 Global Late-Stage Oncology Drug Sales 2019-2030
1.4.3 Global Late-Stage Oncology Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Late-Stage Oncology Drug Market Competition by Manufacturers
2.1 Global Late-Stage Oncology Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Late-Stage Oncology Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Late-Stage Oncology Drug Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Late-Stage Oncology Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Late-Stage Oncology Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Late-Stage Oncology Drug, Product Type & Application
2.7 Global Key Manufacturers of Late-Stage Oncology Drug, Date of Enter into This Industry
2.8 Global Late-Stage Oncology Drug Market Competitive Situation and Trends
2.8.1 Global Late-Stage Oncology Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Late-Stage Oncology Drug Players Market Share by Revenue
2.8.3 Global Late-Stage Oncology Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Late-Stage Oncology Drug Market Scenario by Region
3.1 Global Late-Stage Oncology Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Late-Stage Oncology Drug Sales by Region: 2019-2030
3.2.1 Global Late-Stage Oncology Drug Sales by Region: 2019-2024
3.2.2 Global Late-Stage Oncology Drug Sales by Region: 2025-2030
3.3 Global Late-Stage Oncology Drug Revenue by Region: 2019-2030
3.3.1 Global Late-Stage Oncology Drug Revenue by Region: 2019-2024
3.3.2 Global Late-Stage Oncology Drug Revenue by Region: 2025-2030
3.4 North America Late-Stage Oncology Drug Market Facts & Figures by Country
3.4.1 North America Late-Stage Oncology Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Late-Stage Oncology Drug Sales by Country (2019-2030)
3.4.3 North America Late-Stage Oncology Drug Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Late-Stage Oncology Drug Market Facts & Figures by Country
3.5.1 Europe Late-Stage Oncology Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Late-Stage Oncology Drug Sales by Country (2019-2030)
3.5.3 Europe Late-Stage Oncology Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Late-Stage Oncology Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Late-Stage Oncology Drug Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Late-Stage Oncology Drug Sales by Region (2019-2030)
3.6.3 Asia Pacific Late-Stage Oncology Drug Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Late-Stage Oncology Drug Market Facts & Figures by Country
3.7.1 Latin America Late-Stage Oncology Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Late-Stage Oncology Drug Sales by Country (2019-2030)
3.7.3 Latin America Late-Stage Oncology Drug Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Late-Stage Oncology Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Late-Stage Oncology Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Late-Stage Oncology Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Late-Stage Oncology Drug Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Late-Stage Oncology Drug Sales by Type (2019-2030)
4.1.1 Global Late-Stage Oncology Drug Sales by Type (2019-2024)
4.1.2 Global Late-Stage Oncology Drug Sales by Type (2025-2030)
4.1.3 Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2030)
4.2 Global Late-Stage Oncology Drug Revenue by Type (2019-2030)
4.2.1 Global Late-Stage Oncology Drug Revenue by Type (2019-2024)
4.2.2 Global Late-Stage Oncology Drug Revenue by Type (2025-2030)
4.2.3 Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2030)
4.3 Global Late-Stage Oncology Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Late-Stage Oncology Drug Sales by Application (2019-2030)
5.1.1 Global Late-Stage Oncology Drug Sales by Application (2019-2024)
5.1.2 Global Late-Stage Oncology Drug Sales by Application (2025-2030)
5.1.3 Global Late-Stage Oncology Drug Sales Market Share by Application (2019-2030)
5.2 Global Late-Stage Oncology Drug Revenue by Application (2019-2030)
5.2.1 Global Late-Stage Oncology Drug Revenue by Application (2019-2024)
5.2.2 Global Late-Stage Oncology Drug Revenue by Application (2025-2030)
5.2.3 Global Late-Stage Oncology Drug Revenue Market Share by Application (2019-2030)
5.3 Global Late-Stage Oncology Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Late-Stage Oncology Drug Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Company Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck & Co Late-Stage Oncology Drug Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Bristol Myers
6.3.1 Bristol Myers Company Information
6.3.2 Bristol Myers Description and Business Overview
6.3.3 Bristol Myers Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Bristol Myers Late-Stage Oncology Drug Product Portfolio
6.3.5 Bristol Myers Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Late-Stage Oncology Drug Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Late-Stage Oncology Drug Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AstraZeneca Late-Stage Oncology Drug Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Johnson & Johnson
6.7.1 Johnson & Johnson Company Information
6.7.2 Johnson & Johnson Description and Business Overview
6.7.3 Johnson & Johnson Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Johnson & Johnson Late-Stage Oncology Drug Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Eli Lilly and Company
6.8.1 Eli Lilly and Company Company Information
6.8.2 Eli Lilly and Company Description and Business Overview
6.8.3 Eli Lilly and Company Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Eli Lilly and Company Late-Stage Oncology Drug Product Portfolio
6.8.5 Eli Lilly and Company Recent Developments/Updates
6.9 Sanofi
6.9.1 Sanofi Company Information
6.9.2 Sanofi Description and Business Overview
6.9.3 Sanofi Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sanofi Late-Stage Oncology Drug Product Portfolio
6.9.5 Sanofi Recent Developments/Updates
6.10 AbbVie
6.10.1 AbbVie Company Information
6.10.2 AbbVie Description and Business Overview
6.10.3 AbbVie Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AbbVie Late-Stage Oncology Drug Product Portfolio
6.10.5 AbbVie Recent Developments/Updates
6.11 GSK
6.11.1 GSK Company Information
6.11.2 GSK Description and Business Overview
6.11.3 GSK Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 GSK Late-Stage Oncology Drug Product Portfolio
6.11.5 GSK Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Company Information
6.12.2 Amgen Description and Business Overview
6.12.3 Amgen Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amgen Late-Stage Oncology Drug Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Genentech
6.13.1 Genentech Company Information
6.13.2 Genentech Description and Business Overview
6.13.3 Genentech Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Genentech Late-Stage Oncology Drug Product Portfolio
6.13.5 Genentech Recent Developments/Updates
6.14 Daiichi Sankyo Group
6.14.1 Daiichi Sankyo Group Company Information
6.14.2 Daiichi Sankyo Group Description and Business Overview
6.14.3 Daiichi Sankyo Group Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Daiichi Sankyo Group Late-Stage Oncology Drug Product Portfolio
6.14.5 Daiichi Sankyo Group Recent Developments/Updates
6.15 Aveo Oncology
6.15.1 Aveo Oncology Company Information
6.15.2 Aveo Oncology Description and Business Overview
6.15.3 Aveo Oncology Late-Stage Oncology Drug Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Aveo Oncology Late-Stage Oncology Drug Product Portfolio
6.15.5 Aveo Oncology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Late-Stage Oncology Drug Industry Chain Analysis
7.2 Late-Stage Oncology Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Late-Stage Oncology Drug Production Mode & Process
7.4 Late-Stage Oncology Drug Sales and Marketing
7.4.1 Late-Stage Oncology Drug Sales Channels
7.4.2 Late-Stage Oncology Drug Distributors
7.5 Late-Stage Oncology Drug Customers
8 Late-Stage Oncology Drug Market Dynamics
8.1 Late-Stage Oncology Drug Industry Trends
8.2 Late-Stage Oncology Drug Market Drivers
8.3 Late-Stage Oncology Drug Market Challenges
8.4 Late-Stage Oncology Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Late-Stage Oncology Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Late-Stage Oncology Drug Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global Late-Stage Oncology Drug Market Competitive Situation by Manufacturers in 2023
Table 4. Global Late-Stage Oncology Drug Sales (kg) of Key Manufacturers (2019-2024)
Table 5. Global Late-Stage Oncology Drug Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Late-Stage Oncology Drug Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Late-Stage Oncology Drug Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Late-Stage Oncology Drug Average Price (US$/g) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Late-Stage Oncology Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Late-Stage Oncology Drug, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Late-Stage Oncology Drug, Product Type & Application
Table 12. Global Key Manufacturers of Late-Stage Oncology Drug, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Late-Stage Oncology Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Late-Stage Oncology Drug as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Late-Stage Oncology Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Late-Stage Oncology Drug Sales by Region (2019-2024) & (kg)
Table 18. Global Late-Stage Oncology Drug Sales Market Share by Region (2019-2024)
Table 19. Global Late-Stage Oncology Drug Sales by Region (2025-2030) & (kg)
Table 20. Global Late-Stage Oncology Drug Sales Market Share by Region (2025-2030)
Table 21. Global Late-Stage Oncology Drug Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Late-Stage Oncology Drug Revenue Market Share by Region (2019-2024)
Table 23. Global Late-Stage Oncology Drug Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Late-Stage Oncology Drug Revenue Market Share by Region (2025-2030)
Table 25. North America Late-Stage Oncology Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 27. North America Late-Stage Oncology Drug Sales by Country (2025-2030) & (kg)
Table 28. North America Late-Stage Oncology Drug Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Late-Stage Oncology Drug Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Late-Stage Oncology Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 32. Europe Late-Stage Oncology Drug Sales by Country (2025-2030) & (kg)
Table 33. Europe Late-Stage Oncology Drug Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Late-Stage Oncology Drug Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Late-Stage Oncology Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Late-Stage Oncology Drug Sales by Region (2019-2024) & (kg)
Table 37. Asia Pacific Late-Stage Oncology Drug Sales by Region (2025-2030) & (kg)
Table 38. Asia Pacific Late-Stage Oncology Drug Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Late-Stage Oncology Drug Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Late-Stage Oncology Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 42. Latin America Late-Stage Oncology Drug Sales by Country (2025-2030) & (kg)
Table 43. Latin America Late-Stage Oncology Drug Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Late-Stage Oncology Drug Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa Late-Stage Oncology Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa Late-Stage Oncology Drug Sales by Country (2019-2024) & (kg)
Table 47. Middle East and Africa Late-Stage Oncology Drug Sales by Country (2025-2030) & (kg)
Table 48. Middle East and Africa Late-Stage Oncology Drug Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa Late-Stage Oncology Drug Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Late-Stage Oncology Drug Sales (kg) by Type (2019-2024)
Table 51. Global Late-Stage Oncology Drug Sales (kg) by Type (2025-2030)
Table 52. Global Late-Stage Oncology Drug Sales Market Share by Type (2019-2024)
Table 53. Global Late-Stage Oncology Drug Sales Market Share by Type (2025-2030)
Table 54. Global Late-Stage Oncology Drug Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Late-Stage Oncology Drug Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Late-Stage Oncology Drug Revenue Market Share by Type (2019-2024)
Table 57. Global Late-Stage Oncology Drug Revenue Market Share by Type (2025-2030)
Table 58. Global Late-Stage Oncology Drug Price (US$/g) by Type (2019-2024)
Table 59. Global Late-Stage Oncology Drug Price (US$/g) by Type (2025-2030)
Table 60. Global Late-Stage Oncology Drug Sales (kg) by Application (2019-2024)
Table 61. Global Late-Stage Oncology Drug Sales (kg) by Application (2025-2030)
Table 62. Global Late-Stage Oncology Drug Sales Market Share by Application (2019-2024)
Table 63. Global Late-Stage Oncology Drug Sales Market Share by Application (2025-2030)
Table 64. Global Late-Stage Oncology Drug Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Late-Stage Oncology Drug Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Late-Stage Oncology Drug Revenue Market Share by Application (2019-2024)
Table 67. Global Late-Stage Oncology Drug Revenue Market Share by Application (2025-2030)
Table 68. Global Late-Stage Oncology Drug Price (US$/g) by Application (2019-2024)
Table 69. Global Late-Stage Oncology Drug Price (US$/g) by Application (2025-2030)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 73. Roche Late-Stage Oncology Drug Product
Table 74. Roche Recent Developments/Updates
Table 75. Merck & Co Company Information
Table 76. Merck & Co Description and Business Overview
Table 77. Merck & Co Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 78. Merck & Co Late-Stage Oncology Drug Product
Table 79. Merck & Co Recent Developments/Updates
Table 80. Bristol Myers Company Information
Table 81. Bristol Myers Description and Business Overview
Table 82. Bristol Myers Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 83. Bristol Myers Late-Stage Oncology Drug Product
Table 84. Bristol Myers Recent Developments/Updates
Table 85. Pfizer Company Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 88. Pfizer Late-Stage Oncology Drug Product
Table 89. Pfizer Recent Developments/Updates
Table 90. Novartis Company Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 93. Novartis Late-Stage Oncology Drug Product
Table 94. Novartis Recent Developments/Updates
Table 95. AstraZeneca Company Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 98. AstraZeneca Late-Stage Oncology Drug Product
Table 99. AstraZeneca Recent Developments/Updates
Table 100. Johnson & Johnson Company Information
Table 101. Johnson & Johnson Description and Business Overview
Table 102. Johnson & Johnson Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 103. Johnson & Johnson Late-Stage Oncology Drug Product
Table 104. Johnson & Johnson Recent Developments/Updates
Table 105. Eli Lilly and Company Company Information
Table 106. Eli Lilly and Company Description and Business Overview
Table 107. Eli Lilly and Company Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 108. Eli Lilly and Company Late-Stage Oncology Drug Product
Table 109. Eli Lilly and Company Recent Developments/Updates
Table 110. Sanofi Company Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 113. Sanofi Late-Stage Oncology Drug Product
Table 114. Sanofi Recent Developments/Updates
Table 115. AbbVie Company Information
Table 116. AbbVie Description and Business Overview
Table 117. AbbVie Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 118. AbbVie Late-Stage Oncology Drug Product
Table 119. AbbVie Recent Developments/Updates
Table 120. GSK Company Information
Table 121. GSK Description and Business Overview
Table 122. GSK Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 123. GSK Late-Stage Oncology Drug Product
Table 124. GSK Recent Developments/Updates
Table 125. Amgen Company Information
Table 126. Amgen Description and Business Overview
Table 127. Amgen Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 128. Amgen Late-Stage Oncology Drug Product
Table 129. Amgen Recent Developments/Updates
Table 130. Genentech Company Information
Table 131. Genentech Description and Business Overview
Table 132. Genentech Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 133. Genentech Late-Stage Oncology Drug Product
Table 134. Genentech Recent Developments/Updates
Table 135. Daiichi Sankyo Group Company Information
Table 136. Daiichi Sankyo Group Description and Business Overview
Table 137. Daiichi Sankyo Group Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 138. Daiichi Sankyo Group Late-Stage Oncology Drug Product
Table 139. Daiichi Sankyo Group Recent Developments/Updates
Table 140. Aveo Oncology Company Information
Table 141. Aveo Oncology Description and Business Overview
Table 142. Aveo Oncology Late-Stage Oncology Drug Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2019-2024)
Table 143. Aveo Oncology Late-Stage Oncology Drug Product
Table 144. Aveo Oncology Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Late-Stage Oncology Drug Distributors List
Table 148. Late-Stage Oncology Drug Customers List
Table 149. Late-Stage Oncology Drug Market Trends
Table 150. Late-Stage Oncology Drug Market Drivers
Table 151. Late-Stage Oncology Drug Market Challenges
Table 152. Late-Stage Oncology Drug Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
Table 156. Authors List of This Report


List of Figures
Figure 1. Product Picture of Late-Stage Oncology Drug
Figure 2. Global Late-Stage Oncology Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Late-Stage Oncology Drug Market Share by Type: 2023 & 2030
Figure 4. Chemotherapy Product Picture
Figure 5. Targeted Therapy Product Picture
Figure 6. Immunotherapy Product Picture
Figure 7. Hormonal Therapy Product Picture
Figure 8. Others Product Picture
Figure 9. Global Late-Stage Oncology Drug Market Value by Application (2024-2030) & (US$ Million)
Figure 10. Global Late-Stage Oncology Drug Market Share by Application: 2023 & 2030
Figure 11. Blood Cancer
Figure 12. Breast Cancer
Figure 13. Gastrointestinal Cancer
Figure 14. Prostate Cancer
Figure 15. Respiratory or Lung Cancer
Figure 16. Other
Figure 17. Global Late-Stage Oncology Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Late-Stage Oncology Drug Market Size (2019-2030) & (US$ Million)
Figure 19. Global Late-Stage Oncology Drug Sales (2019-2030) & (kg)
Figure 20. Global Late-Stage Oncology Drug Average Price (US$/g) & (2019-2030)
Figure 21. Late-Stage Oncology Drug Report Years Considered
Figure 22. Late-Stage Oncology Drug Sales Share by Manufacturers in 2023
Figure 23. Global Late-Stage Oncology Drug Revenue Share by Manufacturers in 2023
Figure 24. Global 5 and 10 Largest Late-Stage Oncology Drug Players: Market Share by Revenue in Late-Stage Oncology Drug in 2023
Figure 25. Late-Stage Oncology Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 26. Global Late-Stage Oncology Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 27. North America Late-Stage Oncology Drug Sales Market Share by Country (2019-2030)
Figure 28. North America Late-Stage Oncology Drug Revenue Market Share by Country (2019-2030)
Figure 29. United States Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Canada Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Europe Late-Stage Oncology Drug Sales Market Share by Country (2019-2030)
Figure 32. Europe Late-Stage Oncology Drug Revenue Market Share by Country (2019-2030)
Figure 33. Germany Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. France Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. U.K. Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Italy Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Russia Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Asia Pacific Late-Stage Oncology Drug Sales Market Share by Region (2019-2030)
Figure 39. Asia Pacific Late-Stage Oncology Drug Revenue Market Share by Region (2019-2030)
Figure 40. China Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Japan Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. South Korea Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. India Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Australia Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. China Taiwan Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Latin America Late-Stage Oncology Drug Sales Market Share by Country (2019-2030)
Figure 48. Mexico Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Colombia Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Middle East and Africa Late-Stage Oncology Drug Sales Market Share by Country (2019-2030)
Figure 53. Middle East and Africa Late-Stage Oncology Drug Revenue Market Share by Country (2019-2030)
Figure 54. Turkey Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. UAE Late-Stage Oncology Drug Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Global Sales Market Share of Late-Stage Oncology Drug by Type (2019-2030)
Figure 58. Global Revenue Market Share of Late-Stage Oncology Drug by Type (2019-2030)
Figure 59. Global Late-Stage Oncology Drug Price (US$/g) by Type (2019-2030)
Figure 60. Global Sales Market Share of Late-Stage Oncology Drug by Application (2019-2030)
Figure 61. Global Revenue Market Share of Late-Stage Oncology Drug by Application (2019-2030)
Figure 62. Global Late-Stage Oncology Drug Price (US$/g) by Application (2019-2030)
Figure 63. Late-Stage Oncology Drug Value Chain
Figure 64. Late-Stage Oncology Drug Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock